Making medicine usually takes giant factories. The newest idea needs almost no room at all.
What it needs is zero gravity. So a growing list of drugmakers now runs tests in orbit.
On Earth, gravity messes with how a drug forms. Heavy bits sink, and warm and cool fluids swirl around.
That churn leaves the tiny crystals in a medicine uneven. In space, none of it happens.
With no gravity to tug at them, the crystals grow clean and even. Why does that matter for patients?
Even crystals make a drug thinner and easier to inject. Thick drugs often mean big needles and long, slow drips at a hospital.
Thinner ones can become a quick shot you give yourself at home. That changes the whole patient's day.
We track where new markets like this are opening up in Market Briefs, five minutes each morning, and you get a free investing masterclass when you join.
This isn't a science project anymore. Redwire and others now have real proof it pays off.
It started with Merck. Back in 2014, Merck ran crystal tests on the International Space Station.
That work included its top cancer drug, Keytruda. The tests helped Merck build a version you can inject in just minutes.
It won FDA approval in 2025. Now other drugmakers are lining up.
Redwire's space unit, SpaceMD, has flown 54 tiny drug labs to orbit. It has tested 37 drugs so far.
Big names keep sending it new drugs to try. Eli Lilly and Bristol Myers Squibb are both on that list.
Here's the wild part. You barely need to make any of this stuff.
The active part of a drug is so strong that a tiny bit goes a long way. Varda, another space company, puts the scale in plain terms.
Picture all the crystals needed to dose 450 million people with Pfizer's Covid vaccine. They would fill about two milk jugs.
That tiny size is exactly why the business can work. Varda flies small satellites that make the drug and drop it back to Earth.
Its pitch to drugmakers is simple. As co-founder Delian Asparouhov puts it: "They just send us a drug and we give them back a better drug."
Varda just teamed up with United Therapeutics, too. The plan is to use space to improve a lung-disease drug.
There are real catches here. The space station will shut down in a few years.
And the rockets that bring cargo home safely are still costly. Getting to space is cheap now, but getting back is not.
The drug industry spends hundreds of billions a year on research. Even a small edge in orbit could be worth a lot.
The UK has already mapped out a way to bring space-made drugs to market. Other countries are watching closely.
Morgan Stanley thinks the whole space economy could top $1 trillion by 2040.
A slice of that may end up in your medicine cabinet.
Curious which companies are building the next big market? Read Market Briefs with 350,000+ investors and grab the free 45-minute investing course while you're at it.
